File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Influenza A(H3N2) Antibody Responses to Standard-Dose Versus Enhanced Influenza Vaccine Immunogenicity in Older Adults and Prior Season's Vaccine Status

TitleInfluenza A(H3N2) Antibody Responses to Standard-Dose Versus Enhanced Influenza Vaccine Immunogenicity in Older Adults and Prior Season's Vaccine Status
Authors
Issue Date10-Nov-2023
PublisherOxford University Press
Citation
The Journal of Infectious Diseases, 2023 How to Cite?
Abstract

Background Annual influenza vaccination is recommended for older adults but repeated vaccination with standard-dose influenza vaccine has been linked to reduced immunogenicity and effectiveness, especially against A(H3N2) viruses.Methods Community-dwelling Hong Kong adults aged 65-82 years were randomly allocated to receive 2017-2018 standard-dose quadrivalent, MF59-adjuvanted trivalent, high-dose trivalent, and recombinant-HA quadrivalent vaccination. Antibody response to unchanged A(H3N2) vaccine antigen was compared among participants with and without self-reported prior year (2016-2017) standard-dose vaccination.Results Mean fold rise (MFR) in antibody titers from day 0 to day 30 by hemagglutination inhibition and virus microneutralization assays were lower among 2017-2018 standard-dose and enhanced vaccine recipients with (range, 1.7-3.0) versus without (range, 4.3-14.3) prior 2016-2017 vaccination. MFR was significantly reduced by about one-half to four-fifths for previously vaccinated recipients of standard-dose and all 3 enhanced vaccines (beta range, .21-.48). Among prior-year vaccinated older adults, enhanced vaccines induced higher 1.43 to 2.39-fold geometric mean titers and 1.28 to 1.74-fold MFR versus standard-dose vaccine by microneutralization assay.Conclusions In the context of unchanged A(H3N2) vaccine strain, prior-year vaccination was associated with reduced antibody response among both standard-dose and enhanced influenza vaccine recipients. Enhanced vaccines improved antibody response among older adults with prior-year standard-dose vaccination.

During 2 consecutive years with unchanged A(H3N2) vaccine strain, reduced antibody response was observed in older adults who received prior-year vaccination compared to those who did not, regardless of receiving standard-dose or enhanced influenza vaccines in the current year.


Persistent Identifierhttp://hdl.handle.net/10722/339983
ISSN
2023 Impact Factor: 5.0
2023 SCImago Journal Rankings: 2.387

 

DC FieldValueLanguage
dc.contributor.authorZhong, SY-
dc.contributor.authorNg, TWY-
dc.contributor.authorSkowronski, DM-
dc.contributor.authorIuliano, AD-
dc.contributor.authorLeung, NHL-
dc.contributor.authorPerera, RAPM-
dc.contributor.authorHo, F-
dc.contributor.authorFang, VJ-
dc.contributor.authorTam, YH-
dc.contributor.authorIp, DKM-
dc.contributor.authorHavers, FG-
dc.contributor.authorFry, AM-
dc.contributor.authorAziz-Baumgartner, E-
dc.contributor.authorBarr, IG-
dc.contributor.authorPeiris, M-
dc.contributor.authorThompson, MG-
dc.contributor.authorCowling, BJ-
dc.date.accessioned2024-03-11T10:40:47Z-
dc.date.available2024-03-11T10:40:47Z-
dc.date.issued2023-11-10-
dc.identifier.citationThe Journal of Infectious Diseases, 2023-
dc.identifier.issn0022-1899-
dc.identifier.urihttp://hdl.handle.net/10722/339983-
dc.description.abstract<p>Background Annual influenza vaccination is recommended for older adults but repeated vaccination with standard-dose influenza vaccine has been linked to reduced immunogenicity and effectiveness, especially against A(H3N2) viruses.Methods Community-dwelling Hong Kong adults aged 65-82 years were randomly allocated to receive 2017-2018 standard-dose quadrivalent, MF59-adjuvanted trivalent, high-dose trivalent, and recombinant-HA quadrivalent vaccination. Antibody response to unchanged A(H3N2) vaccine antigen was compared among participants with and without self-reported prior year (2016-2017) standard-dose vaccination.Results Mean fold rise (MFR) in antibody titers from day 0 to day 30 by hemagglutination inhibition and virus microneutralization assays were lower among 2017-2018 standard-dose and enhanced vaccine recipients with (range, 1.7-3.0) versus without (range, 4.3-14.3) prior 2016-2017 vaccination. MFR was significantly reduced by about one-half to four-fifths for previously vaccinated recipients of standard-dose and all 3 enhanced vaccines (beta range, .21-.48). Among prior-year vaccinated older adults, enhanced vaccines induced higher 1.43 to 2.39-fold geometric mean titers and 1.28 to 1.74-fold MFR versus standard-dose vaccine by microneutralization assay.Conclusions In the context of unchanged A(H3N2) vaccine strain, prior-year vaccination was associated with reduced antibody response among both standard-dose and enhanced influenza vaccine recipients. Enhanced vaccines improved antibody response among older adults with prior-year standard-dose vaccination.</p><p>During 2 consecutive years with unchanged A(H3N2) vaccine strain, reduced antibody response was observed in older adults who received prior-year vaccination compared to those who did not, regardless of receiving standard-dose or enhanced influenza vaccines in the current year.</p>-
dc.languageeng-
dc.publisherOxford University Press-
dc.relation.ispartofThe Journal of Infectious Diseases-
dc.titleInfluenza A(H3N2) Antibody Responses to Standard-Dose Versus Enhanced Influenza Vaccine Immunogenicity in Older Adults and Prior Season's Vaccine Status-
dc.typeArticle-
dc.identifier.doi10.1093/infdis/jiad497-
dc.identifier.eissn1537-6613-
dc.identifier.issnl0022-1899-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats